KIF5B-RET fusions in lung adenocarcinoma

被引：631

作者：

Kohno, Takashi ^{[1
]}

Ichikawa, Hitoshi ^{[2
]}

Totoki, Yasushi ^{[3
]}

Yasuda, Kazuki ^{[4
]}

Hiramoto, Masaki ^{[4
]}

Nammo, Takao ^{[4
]}

Sakamoto, Hiromi ^{[2
]}

Tsuta, Koji ^{[5
]}

Furuta, Koh ^{[5
]}

Shimada, Yoko ^{[1
]}

Iwakawa, Reika ^{[6
]}

Ogiwara, Hideaki ^{[1
]}

Oike, Takahiro ^{[6
]}

Enari, Masato ^{[7
]}

Schetter, Aaron J. ^{[8
]}

Okayama, Hirokazu ^{[6
,8
]}

Haugen, Aage ^{[9
]}

Skaug, Vidar ^{[9
]}

Chiku, Suenori ^{[10
]}

Yamanaka, Itaru ^{[11
]}

Arai, Yasuhito

Watanabe, Shun-ichi ^{[12
]}

Sekine, Ikuo ^{[13
]}

Ogawa, Seishi ^{[14
]}

Harris, Curtis C. ^{[8
]}

Tsuda, Hitoshi ^{[5
]}

Yoshida, Teruhiko ^{[2
]}

Yokota, Jun ^{[6
]}

Shibata, Tatsuhiro ^{[3
]}

机构：

[1] Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, Tokyo 104, Japan

[2] Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 104, Japan

[3] Natl Canc Ctr, Res Inst, Div Canc Genom, Chuo Ku, Tokyo 104, Japan

[4] Natl Ctr Global Hlth & Med, Dept Metab Disorder, Diabet Res Ctr, Res Inst,Shinjuku Ku, Tokyo, Japan

[5] Natl Canc Ctr, Div Pathol & Clin Labs, Chuo Ku, Tokyo, Japan

[6] Natl Canc Ctr, Res Inst, Div Multistep Carcinogenesis, Chuo Ku, Tokyo 104, Japan

[7] Natl Canc Ctr, Res Inst, Div Refractory Canc Res, Tokyo 104, Japan

[8] NCI, Human Carcinogenesis Lab, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA

[9] Natl Inst Occupat Hlth, Sect Toxicol, Dept Chem & Biol Working Environm, Oslo, Norway

[10] Mizuho Informat & Res Inst, Sci Solut Div, Chiyoda Ku, Tokyo, Japan

[11] StaGen, Stat Genet Anal Div, Taito Ku, Tokyo, Japan

[12] Natl Canc Ctr, Div Thorac Surg, Chuo Ku, Tokyo, Japan

[13] Natl Canc Ctr, Div Thorac Oncol, Chuo Ku, Tokyo, Japan

[14] Univ Tokyo, Bunkyo Ku, Canc Genom Project, Tokyo 113, Japan

来源：

NATURE MEDICINE | 2012年 / 18卷 / 03期

关键词：

CANCER; RET; IDENTIFICATION; THERAPY;

D O I：

10.1038/nm.2644

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.

引用

页码：375 / 377

页数：3

共 50 条

[1] KIF5B-RET fusions in lung adenocarcinoma
Takashi Kohno
Hitoshi Ichikawa
Yasushi Totoki
Kazuki Yasuda
Masaki Hiramoto
Takao Nammo
Hiromi Sakamoto
Koji Tsuta
Koh Furuta
Yoko Shimada
Reika Iwakawa
Hideaki Ogiwara
Takahiro Oike
Masato Enari
Aaron J Schetter
Hirokazu Okayama
Aage Haugen
Vidar Skaug
Suenori Chiku
Itaru Yamanaka
Yasuhito Arai
Shun-ichi Watanabe
Ikuo Sekine
Seishi Ogawa
Curtis C Harris
Hitoshi Tsuda
Teruhiko Yoshida
Jun Yokota
Tatsuhiro Shibata
[J]. Nature Medicine, 2012, 18 : 375 - 377
[2] Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma
Huang, Qingling
Schneeberger, Valentina E.
Luetteke, Noreen
Jin, Chengliu
Afzal, Roha
Budzevich, Mikalai M.
Makanji, Rikesh J.
Martinez, Gary V.
Shen, Tao
Zhao, Lichao
Fung, Kar-Ming
Haura, Eric B.
Coppola, Domenico
Wu, Jie
[J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (10) : 2521 - 2529
[3] Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma
Go, Heounjeong
Jung, Yoo Jin
Kang, Hyun Woong
Park, In-Kyu
Kang, Chang-Hyun
Lee, Jung Wan
Ju, Young Seok
Seo, Jeong-Sun
Chung, Doo Hyun
Kim, Young Tae
[J]. LUNG CANCER, 2013, 82 (01) : 44 - 50
[4] KIF5B-RET fusions in Chinese patients with nonsmall cell lung cancer
Cai, Weijing
Su, Chunxia
Li, Xuefei
Fan, Lihong
Zheng, Limou
Fei, Ke
Zhou, Caicun
[J]. CANCER, 2013, 119 (08) : 1486 - 1494
[5] NEOliquid: Detection of KIF5B-RET fusions in liquid biopsy samples
Heukamp, L.
Menon, R.
Mueller, J.
Lakis, S.
Netchaeva, M.
Griesinger, F.
Eberhardt, W.
Heuckmann, J. M.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S82 - S83
[6] Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene
Wu, Hsu
Shih, Jin-Yuan
Yang, James Chih-Hsin
[J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : E95 - E96
[7] A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis
Saito, Motonobu
Ishigame, Teruhide
Tsuta, Koji
Kumamoto, Kensuke
Imai, Toshio
Kohno, Takashi
[J]. CARCINOGENESIS, 2014, 35 (11) : 2452 - 2456
[8] The KIF5B-RET Fusion as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma
Zhu, Y.
Wang, W.
Xu, C.
Zhang, Q.
Zhuang, W.
Du, K.
Chen, G.
Fang, M.
Lv, T.
Song, Y.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1049 - S1049
[9] Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib
Zheng, Qiufan
Fang, Wenfeng
Huang, Yihua
Gan, Jiadi
Zhang, Li
[J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (08) : E132 - E133
[10] Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens
Capelletti, Marzia
Lipson, Doron
Otto, Geoff
Yelensky, Roman
Ercan, Dalia
Kim, Jhingook
Sasaki, Hidefumi
Kim, Hyeong Ryul
Park, Seung-Il
Ross, Jeffrey S.
Stephens, Philip
Cronin, Maureen T.
Janne, Pasi Antero
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →